Riffat Shaheen, Hussaini Bala, Ahmad Haruna Abubakar, Supriya Lamba Sahdev, Armaya'u Alhaji Sani, Ghousia Khatoon, Umair Zahid
{"title":"Revisiting the Governance-Dividend Nexus: The Mediating Role of Corporate Social Responsibility.","authors":"Riffat Shaheen, Hussaini Bala, Ahmad Haruna Abubakar, Supriya Lamba Sahdev, Armaya'u Alhaji Sani, Ghousia Khatoon, Umair Zahid","doi":"10.12688/f1000research.167892.3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite plentiful research on the link between corporate governance (CG) and dividend policy, the mediating impact of corporate social responsibility (CSR) on the CG -dividend policy link remains unexplored. This study investigates the mediating impact of CSR on the CG -dividend policy link, and explores the mechanism through which CSR mediates this relationship.</p><p><strong>Methods: </strong>Firms listed on the Shanghai and Shenzhen stock exchanges are considered as a study sample. The data collection period ranged from 2012 to 2021. The final sample included 15,800 firm-year observations.</p><p><strong>Results: </strong>The results findings indicate that firms with strong CG tend to pay low dividends, consistent with the substitution hypothesis, in which dividends and CG act as substitutes for each other. In addition to establishing a direct link between CG and dividend policy, our study significantly contributes to the extant literature by presenting both theoretical proposition and empirical evidence on the mediation effect of CSR in the above-mentioned relationship. We find that CSR mediates the corporate governance- dividend policy relationship, which implies that in comparison to corporate governance, CSR has a more dominating impact on firms' dividend policy decisions, and better-governed firms are more likely to engage in CSR activities to protect their stakeholders; consequently, they prefer to hold or invest cash instead of paying dividends because CSR engagements lower the cost of equity capital. These findings were corroborated by a set of robustness tests.</p><p><strong>Conclusions: </strong>Our results have several implications for firms, regulators, and investors. Firms can use high dividend payouts to compensate for poor investor protection and to maintain good relationships with investors. When making investment decisions, investors are advised to consider socially responsible firms because of their strong CG structure. Finally, policy makers should give special consideration to CSR in order to reduce environmental and social problems and to enhance the related standards to ensure the safety and security of all stakeholders and hence reduce global accusation and pressure.</p>","PeriodicalId":12260,"journal":{"name":"F1000Research","volume":"14 ","pages":"886"},"PeriodicalIF":0.0000,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13062773/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"F1000Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12688/f1000research.167892.3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Despite plentiful research on the link between corporate governance (CG) and dividend policy, the mediating impact of corporate social responsibility (CSR) on the CG -dividend policy link remains unexplored. This study investigates the mediating impact of CSR on the CG -dividend policy link, and explores the mechanism through which CSR mediates this relationship.
Methods: Firms listed on the Shanghai and Shenzhen stock exchanges are considered as a study sample. The data collection period ranged from 2012 to 2021. The final sample included 15,800 firm-year observations.
Results: The results findings indicate that firms with strong CG tend to pay low dividends, consistent with the substitution hypothesis, in which dividends and CG act as substitutes for each other. In addition to establishing a direct link between CG and dividend policy, our study significantly contributes to the extant literature by presenting both theoretical proposition and empirical evidence on the mediation effect of CSR in the above-mentioned relationship. We find that CSR mediates the corporate governance- dividend policy relationship, which implies that in comparison to corporate governance, CSR has a more dominating impact on firms' dividend policy decisions, and better-governed firms are more likely to engage in CSR activities to protect their stakeholders; consequently, they prefer to hold or invest cash instead of paying dividends because CSR engagements lower the cost of equity capital. These findings were corroborated by a set of robustness tests.
Conclusions: Our results have several implications for firms, regulators, and investors. Firms can use high dividend payouts to compensate for poor investor protection and to maintain good relationships with investors. When making investment decisions, investors are advised to consider socially responsible firms because of their strong CG structure. Finally, policy makers should give special consideration to CSR in order to reduce environmental and social problems and to enhance the related standards to ensure the safety and security of all stakeholders and hence reduce global accusation and pressure.
F1000ResearchPharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
5.00
自引率
0.00%
发文量
1646
审稿时长
1 weeks
期刊介绍:
F1000Research publishes articles and other research outputs reporting basic scientific, scholarly, translational and clinical research across the physical and life sciences, engineering, medicine, social sciences and humanities. F1000Research is a scholarly publication platform set up for the scientific, scholarly and medical research community; each article has at least one author who is a qualified researcher, scholar or clinician actively working in their speciality and who has made a key contribution to the article. Articles must be original (not duplications). All research is suitable irrespective of the perceived level of interest or novelty; we welcome confirmatory and negative results, as well as null studies. F1000Research publishes different type of research, including clinical trials, systematic reviews, software tools, method articles, and many others. Reviews and Opinion articles providing a balanced and comprehensive overview of the latest discoveries in a particular field, or presenting a personal perspective on recent developments, are also welcome. See the full list of article types we accept for more information.